Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2020
SIETES contiene 92913 citas

 
 
 1 a 20 de 201 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;381:29 de agosto. [Ref.ID 102748]
2.Tiene citas relacionadas Cita con resumen
Rasmussen SA, Barfield W, Honein MA. Protecting mothers and babies — A delicate balancing act. N Engl J Med 2018:24 de julio. [Ref.ID 102747]
3. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
4. Cita con resumen
Anónimo. Rilpivirine et HIV chez les adolescents. Prescrire 2017;37:13-4. [Ref.ID 101362]
5. Cita con resumen
Anónimo. Éfavirenz: suicides. Prescrire 2015;35:105. [Ref.ID 98917]
6. Cita con resumen
Anónimo. Ginkgo biloba: diminution d'efficacité de l'éfavirenz. Prescrire 2014;34:749. [Ref.ID 98264]
7. Cita con resumen
Anónimo. Dolutégravir. Prescrire 2014;34:414-5. [Ref.ID 97945]
8. Cita con resumen
Anónimo. FDA approves new treatment for HIV In adults. DIA Daily 2014:25 de agosto. [Ref.ID 97864]
9. Cita con resumen
Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbel TB, Sax PE, Gulick RM, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014;161:1-10. [Ref.ID 97795]
11.Enlace a cita original Cita con resumen
Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, Dollfus C, Tubiana R, Bonnet D, Lelong N, Khoshnood B, Warszawski J. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLOS Medicine 2014;11:1001635. [Ref.ID 97536]
12.Tiene citas relacionadas Cita con resumen
Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]
13. Cita con resumen
Anónimo. Cobicistat + elvitégravir + emtricitabine + ténofovir. Prescrire 2013;33:408-11. [Ref.ID 95570]
14. Cita con resumen
Sherer R. Generic antiretrovirals and the uncertain future of HIV care in the United States. Ann Intern Med 2013;158:133-4. [Ref.ID 94776]
15.
Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011;343:1060-3. [Ref.ID 91842]
16.
Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers LK, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, for the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. A randomized trial. Ann Intern Med 2011;154:445-56. [Ref.ID 91259]
17. Cita con resumen
Anónimo. FDA approves once-daily combination or treatment-naive HIV patients.. DIA Daily 2011:11 agosto. [Ref.ID 91191]
18. Cita con resumen
Anónimo. Rilpivirine (Edurant) - A new drug for HIV infection. Med Lett Drugs Ther 2011;53:67-8. [Ref.ID 91033]
19.Tiene citas relacionadas Cita con resumen
Molina J-M, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, on behalf of the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46. [Ref.ID 90875]
20.Tiene citas relacionadas Cita con resumen
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K, on behalf of the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37. [Ref.ID 90874]
Seleccionar todas
 
 1 a 20 de 201 siguiente >>